eMed

Dr. Patrice Harris, a former president of the American Medical Association, serves as CEO and co-founder, bringing physician leadership and regulatory expertise to the firm's operations. Dr. Michael Mina, an epidemiologist formerly at Harvard's T.H. Chan School of Public Health, serves as Chief Science Officer and co-founder, driving the diagnostic testing and public-health strategy. Their combined clinical and scientific backgrounds position the firm at the intersection of regulated medical practice and scalable public-health logistics.

eMed integrates FDA-authorized diagnostic test distribution with synchronous, proctored telehealth sessions that are required to validate at-home test results under certain FDA protocols. This is not a software layer on third-party labs — the firm controls the physical test-kit supply chain, the remote verification step, and the downstream care-navigation pathway. The result is a vertically integrated diagnostic provider that carries full regulatory responsibility for result accuracy and clinical follow-up.

In January 2022, the US Department of Health and Human Services awarded eMed a contract valued at up to $1.2 billion to serve as a distribution and telehealth verification partner for the White House's program to mail free rapid antigen tests to American households. eMed's platform handled logistics and the FDA-required proctored verification step for test results, positioning the firm as a critical node in the national public-health infrastructure during the Omicron wave.

The platform's catalog includes FDA-authorized at-home test kits for Covid-19, influenza A/B, and combination respiratory panels, all paired with live telehealth proctoring. eMed has expanded beyond infectious disease into remote patient monitoring for chronic conditions including hypertension and diabetes, using connected devices and clinician-guided workflows to support ongoing care outside clinical settings.

eMed sells direct-to-consumer through its website, partners with employers for workforce wellness programs, and maintains significant government contracting relationships, most visibly with HHS during the pandemic. The firm also works with airlines and hospitality operators that require proctored testing for travelers, though the scale of that segment has shifted with pandemic-era travel policies.

eMed is a privately held company. The firm has raised venture capital funding, with notable investors including stated backing from firms active in health-tech and logistics sectors, though specific fundraise amounts and participating investors beyond public record rounds are not fully disclosed. The $1.2 billion HHS contract in 2022 also provided substantial non-dilutive revenue.

eMed procures FDA-authorized rapid antigen and molecular test kits from established diagnostics manufacturers and bundles them with its telehealth verification platform. By controlling the fulfillment and verification layers rather than manufacturing the physical tests, the firm maintains supply-chain flexibility while acting as the regulated provider of record for the results.